Cytopathological evaluation of various thyroid lesions based on Bethesda system for reporting thyroid lesions

Ashwini S. Khadatkar, Varsha M. Dhume, Vikas Kavishwar


Background: An encouragement for the thyroid proposal was the Bethesda system for reporting cervical cytology interpretations, a uniform reporting system for thyroid FNA will facilitate effective communication among health care providers. The objective of the present study was to classify thyroid lesions in various categories under Bethesda system correlating the cytological findings in various thyroid lesions with clinical and radiological details.

Methods: A retrospective study on FNAC thyroid was performed in a tertiary hospital and a Medical teaching institution in Mumbai, Maharashtra, India which included cases which were reported from 1st January 2010 to 31st July 2011. For cytomorphological analysis, all smears (Papanicolaou and MGG) were reviewed and cases were categorized into six Bethesda categories. The FNAC findings were correlated with clinical, radiological and laboratory findings. Discrepancies between original diagnosis and review diagnosis as well as difficulties encountered during application of Bethesda were studied in detail.

Results: Total 413 FNACs were received during the study period. The original diagnoses included 10 different categories or labels some of which were descriptive. On application of Bethesda, maximum cases were found in category II (82.32%) followed by category I i.e. inadequate (7.7%). Category III (Atypia of Undetermined significance) included wide spectrum of cases which were previously diagnosed as goitre, suspicious or neoplastic.

Conclusions: Bethesda system of reporting thyroid FNAC has brought uniformity in cytology reporting. It has facilitated better understanding between cytopathologist and clinicians as every category connotes specific risk of malignancy and recommends treatment.


AUS category, Benign and malignant lesions, Bethesda system, FNAC

Full Text:



Dash M, Chandrashekhar KPA, Raghu K, Saadvi K. Histopathological study of neoplastic and non-neoplastic thyroid lesions: an institutional experience of 2 years. JEMDS. 2016;5(73):5348-51.

Gupta M, Gupta S, Gupta VB. Correlation of fine needle aspiration cytology with histopathology in the diagnosis of solitary thyroid nodule. J Thyroid Res. 2010;2010:379051.

Para R. Bethesda system of reporting thyroid cytopathology- a study of 100 cases. NJIRM. 2016;7(3):52-4.

Ali SZ. Thyroid cytopathology: Bethesda and beyond. Acta Cytologica. 2011;55:4-12.

Jing X, Knoepp SM, Roh MH. Consensual review minimizes the diagnosis of ‘‘follicular lesion of undetermined significance’’ and improves reproducibility and cyto-histologic concordance. Diagn Cytopathol. 2012;40:1037-42.

Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010;134:450-6.

Marchevsky AM, Walts AE, Bose S. Evidence-based evaluation of the risks of malignancy predicted by thyroid fine needles aspiration biopsies. Diagn Cytopathol. 2010;38:252-9.

Renshaw AA. Sub classification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. Cancer Cytopathol. 2011;119:322-7.

Unnikrishnan AG, Kalra S, Baruah M. Endocrine society of India management guidelines for patients with thyroid nodules: A position statement. Indian J Endol Metab. 2011;15:2-8.

Tsegaye B, Ergete W, Histologic pattern of thyroid disease. East Afr Med J. 2003;80:525-8.

Mandakini MP, Komal P, Kumarbhargav RK. Fine needle aspiration cytology as a first line investigation in thyroid lesions. Natl J Med Res. 2013;45:106-109.

Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic centre using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117:195-202.